Sensei Bio - Sensei Biotherapeutics

We push the boundaries of science and imagination to discover and develop innovative medicines for patients

Learn More

The Science of Saving Lives

About

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancers and infectious disease.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.

Learn More

Editable

Vaccine editing on the fly

Tolerable

Well Tolerated

Scalable

Cost effective, fast and scalable

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Meet Our Leaders

In the News

Sorting:

Sort Descending

Sensei Biotherapeutics Announces Closing of Initial Public Offering
February 10, 2021
BOSTON and ROCKVILLE, Md. , Feb. 10, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares ofRead More
Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering
February 3, 2021
BOSTON and ROCKVILLE, Md. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. , a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsized initial public offering of 7,000,052Read More
Sensei Biotherapeutics Announces Launch of Initial Public Offering
February 1, 2021
BOSTON, MA and ROCKVILLE, MD – February 1, 2021 – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that it has launched an underwritten initial public offering of 5,885,000Read More

12 3 4 ›»

Previous tab Next tab

All News